Therapeutic Area | MeSH |
---|---|
cardiovascular diseases | D002318 |
nutritional and metabolic diseases | D009750 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ALTOPREV | Covis Pharma | N-021316 DISCN | 2002-06-26 | 4 products, RLD |
MEVACOR | Merck & Co | N-019643 DISCN | 1987-08-31 | 3 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
advicor | New Drug Application | 2012-10-04 |
altoprev | New Drug Application | 2024-12-31 |
lovastatin | ANDA | 2025-08-26 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
hypercholesterolemia | — | D006937 | — |
coronary artery disease | — | D003324 | I25.1 |
hypertriglyceridemia | EFO_0004211 | D015228 | — |
hyperlipoproteinemias | — | D006951 | — |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypercholesterolemia | D006937 | — | — | 4 | 5 | 58 | 27 | 21 | 115 |
Dyslipidemias | D050171 | — | — | 4 | 3 | 25 | 10 | 7 | 49 |
Healthy volunteers/patients | — | — | — | 33 | 1 | — | 4 | 3 | 41 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 2 | 15 | 11 | 11 | 39 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 10 | 1 | 10 | 9 | 5 | 35 |
Coronary disease | D003327 | — | — | — | 1 | 15 | 12 | 4 | 32 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 2 | 4 | 10 | 9 | 7 | 31 |
Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | 1 | 1 | 15 | 8 | 6 | 30 |
Atherosclerosis | D050197 | EFO_0003914 | I25.1 | 1 | 3 | 8 | 10 | 8 | 29 |
Coronary artery disease | D003324 | — | I25.1 | 1 | 1 | 9 | 12 | 6 | 28 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hemorrhage | D006470 | MP_0001914 | R58 | 2 | 4 | 3 | — | 1 | 7 |
Colorectal neoplasms | D015179 | — | — | — | 4 | 1 | — | — | 5 |
Vascular diseases | D014652 | EFO_0004264 | I77 | — | 1 | 4 | — | — | 5 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 4 | 1 | — | — | 5 |
Carotid artery diseases | D002340 | EFO_0003781 | — | — | 1 | 1 | — | 3 | 5 |
Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | 2 | 3 | 2 | — | 1 | 5 |
Covid-19 | D000086382 | — | U07.1 | 1 | 1 | 2 | — | — | 4 |
Asthma | D001249 | EFO_0000270 | J45 | 1 | 2 | 2 | — | — | 4 |
Sickle cell anemia | D000755 | EFO_0000697 | D57 | 3 | 4 | 1 | — | — | 4 |
Hyperlipoproteinemia type ii | D006938 | EFO_0004911 | E78.00 | — | — | 4 | — | — | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 11 | — | — | — | 13 |
Prostatic neoplasms | D011471 | — | C61 | 1 | 4 | — | — | 3 | 8 |
Neoplasms | D009369 | — | C80 | 5 | 2 | — | — | 2 | 8 |
Multiple myeloma | D009101 | — | C90.0 | 2 | 4 | — | — | 1 | 6 |
Plasma cell neoplasms | D054219 | — | — | 2 | 4 | — | — | 1 | 6 |
Lung neoplasms | D008175 | — | C34.90 | — | 5 | — | — | — | 5 |
Small cell lung carcinoma | D055752 | — | — | — | 4 | — | — | — | 4 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 3 | — | — | — | 4 |
Neurofibromatosis 1 | D009456 | — | Q85.01 | 1 | 2 | — | — | 1 | 4 |
Neurofibromatoses | D017253 | — | Q85.00 | 1 | 2 | — | — | 1 | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 3 | — | — | — | — | 3 |
Acute kidney injury | D058186 | — | N17 | 1 | — | — | — | 2 | 3 |
Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | — | — | — | 1 | 2 |
Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
Neurotoxicity syndromes | D020258 | — | G92 | 1 | — | — | — | — | 1 |
Lipodystrophy | D008060 | — | E88.1 | 1 | — | — | — | — | 1 |
Hiv seronegativity | D018023 | — | — | 1 | — | — | — | — | 1 |
Hepatitis b | D006509 | — | — | 1 | — | — | — | — | 1 |
Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 1 | — | — | — | — | 1 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myalgia | D063806 | — | M79.1 | — | — | — | — | 2 | 2 |
Congenital heart defects | D006330 | — | Q24.9 | — | — | — | — | 2 | 2 |
Heart valve diseases | D006349 | EFO_0009551 | I08 | — | — | — | — | 2 | 2 |
Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 2 | 2 |
Chest pain | D002637 | — | R07.9 | — | — | — | — | 1 | 1 |
Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | — | — | 1 | 1 |
Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | — | — | 1 | 1 |
Cytokinesis | D048749 | — | — | — | — | — | — | 1 | 1 |
Thyroid neoplasms | D013964 | EFO_0003841 | — | — | — | — | — | 1 | 1 |
Anaplastic thyroid carcinoma | D065646 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Lovastatin |
INN | lovastatin |
Description | Lovastatin is a fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom). It has a role as an Aspergillus metabolite, a prodrug, an anticholesteremic drug and an antineoplastic agent. It is a polyketide, a statin (naturally occurring), a member of hexahydronaphthalenes, a delta-lactone and a fatty acid ester. It is functionally related to a (S)-2-methylbutyric acid and a mevastatin. |
Classification | Small molecule |
Drug class | enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21 |
PDB | — |
CAS-ID | 75330-75-5 |
RxCUI | — |
ChEMBL ID | CHEMBL503 |
ChEBI ID | 40303 |
PubChem CID | 53232 |
DrugBank | DB00227 |
UNII ID | 9LHU78OQFD (ChemIDplus, GSRS) |